<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576342</url>
  </required_header>
  <id_info>
    <org_study_id>C-07-47</org_study_id>
    <nct_id>NCT00576342</nct_id>
  </id_info>
  <brief_title>Patient Preference Study</brief_title>
  <official_title>A Single Dose Patient Preference Study Comparison in Patients With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized crossover study, patients will receive a single drop of two test articles
      and assess comfort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with a stated preference for either study medication</measure>
    <time_frame>Day 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean ocular discomfort score</measure>
    <time_frame>Day 1, 1 minute after drop instillation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>AL-3862+timolol, then COSOPT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COSOPT, then AL-3862+timolol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-3862+timolol ophthalmic suspension</intervention_name>
    <arm_group_label>AL-3862+timolol, then COSOPT</arm_group_label>
    <arm_group_label>COSOPT, then AL-3862+timolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dorzolamide+timolol ophthalmic solution</intervention_name>
    <arm_group_label>AL-3862+timolol, then COSOPT</arm_group_label>
    <arm_group_label>COSOPT, then AL-3862+timolol</arm_group_label>
    <other_name>COSOPT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign informed consent;

          -  Diagnosis of glaucoma or ocular hypertension;

          -  On a stable regimen of any intraocular pressure (IOP) lowering medication
             (mono-therapy);

          -  IOP for which, in the opinion of the investigator, participation in the study does not
             present a risk to ocular health;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Best corrected visual acuity worse than 0.60 logMAR (20/80 Snellen) in either eye;

          -  Pregnant, nursing, or not using highly effective birth control methods;

          -  Use of oral or topical corticosteroids within 30 days of the Screening Visit and
             during the course of the study;

          -  History of bronchial asthma or severe chronic obstructive pulmonary disease;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <disposition_first_submitted>July 9, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 9, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 11, 2014</disposition_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

